KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to -$5.9 million.

  • Co-Diagnostics' Cash from Operations rose 1832.66% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.2 million, marking a year-over-year decrease of 2126.62%. This contributed to the annual value of -$29.2 million for FY2024, which is 3203.16% down from last year.
  • Co-Diagnostics' Cash from Operations amounted to -$5.9 million in Q3 2025, which was up 1832.66% from -$8.3 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Cash from Operations ranged from a high of $12.4 million in Q2 2021 and a low of -$8.7 million during Q1 2025
  • Its 5-year average for Cash from Operations is -$1.4 million, with a median of -$5.2 million in 2024.
  • In the last 5 years, Co-Diagnostics' Cash from Operations surged by 115869.07% in 2021 and then tumbled by 61551.98% in 2023.
  • Over the past 5 years, Co-Diagnostics' Cash from Operations (Quarter) stood at $4.9 million in 2021, then tumbled by 182.19% to -$4.0 million in 2022, then decreased by 19.17% to -$4.8 million in 2023, then tumbled by 72.25% to -$8.2 million in 2024, then grew by 28.26% to -$5.9 million in 2025.
  • Its Cash from Operations was -$5.9 million in Q3 2025, compared to -$8.3 million in Q2 2025 and -$8.7 million in Q1 2025.